Core Insights - Maiwei Biotech has received approval from the National Medical Products Administration for the Phase II clinical trial application of 9MW3811 injection for pathological scars, potentially becoming the first IL-11 targeted drug to enter clinical stages for this indication [1] Group 1: Clinical Development - The Phase II clinical trial for 9MW3811 is planned to start by the end of 2025, marking a significant milestone in the treatment of pathological scars [1] - 9MW3811 has already been approved for clinical research in advanced malignant tumors and idiopathic pulmonary fibrosis globally, having completed Phase I trials in Australia and China [1] Group 2: Licensing Agreement - The company has entered into an exclusive licensing agreement with CALICO Life Sciences LLC, granting CALICO global rights outside of Greater China [1] - CALICO has made an upfront payment of $25 million to the company, with potential milestone payments reaching up to $571 million related to near-term, development, registration, and commercialization [1]

Core Viewpoint - Maiwei Biotech (688062.SH) has received approval from the National Medical Products Administration for the clinical trial of 9MW3811 injection for pathological scar indications, marking a significant advancement in its research and development pipeline [1] Group 1: Clinical Trial Approval - The company announced that it has obtained the Clinical Trial Approval Notice for 9MW3811 injection, which is intended for use in pathological scar indications [1] - The II phase clinical trial for 9MW3811 is planned to start by the end of 2025, making it the first IL-11 targeted drug to enter clinical stages in this indication area [1] Group 2: Global Research and Development Progress - 9MW3811 has already been approved for clinical research in advanced malignant tumors and idiopathic pulmonary fibrosis globally, having completed Phase I trials in Australia and China [1] - The development progress of 9MW3811 is currently leading among global peers targeting similar pathways [1] Group 3: Licensing Agreement - The company has entered into an exclusive licensing agreement with CALICO Life Sciences LLC, granting CALICO global rights outside Greater China [1] - CALICO has made an upfront payment of $25 million to the company, with potential milestone payments reaching up to $571 million for near-term, development, registration, and commercialization milestones [1]

Core Viewpoint - Maiwei Biotech has received the acceptance notice from the National Medical Products Administration for the Phase II clinical trial application of 9MW3811 injection for pathological scars, marking a significant step in its development pipeline [1] Group 1: Product Development - 9MW3811 is a humanized monoclonal antibody targeting human IL-11, developed independently by Maiwei Biotech and holds proprietary intellectual property [1] - Preclinical studies have demonstrated significant efficacy of 9MW3811 in various models, including pulmonary fibrosis, and it shows potential application value in fibrosis-related diseases such as scar hyperplasia and abnormal uterine bleeding [1] - The company plans to initiate the Phase II clinical trial for 9MW3811 targeting pathological scars by the end of 2025, positioning it as one of the first IL-11 targeted drugs to enter clinical stages in this indication area [1]